X

Trial Profile

A Pilot Study of Neoadjuvant Cemiplimab With Platinum-Doublet Chemotherapy, and Cetuximab in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cemiplimab (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Paranasal sinus diseases; Squamous cell cancer
Focus Adverse reactions

Most Recent Events

03 Jul 2023 Planned End Date changed from 20 Jun 2023 to 20 Jun 2026.
03 Jul 2023 Planned primary completion date changed from 20 Jun 2023 to 20 Jun 2026.
06 Jun 2023 Results (n=10) reporting toxicity data presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com